Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valesca P Retèl

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Molecular profiling is rather likely to be cost effectiveValesca P Retèl, Sabine C Linn, Wim H van Harten
Breast Cancer Research and Treatment|September 28, 2011
Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of complianceValesca P Retèl, Manuela A Joore, Wim H van Harten
Molecular Oncology|June 23, 2009
Review on early technology assessments of nanotechnologies in oncologyValesca P Retèl, Marjan J M Hummel, Wim H van Harten
JAMA Oncology|March 28, 2020
Evidence Underlying Policy Proposals for Sustainable Anticancer Drug Prices: A Systematic ReviewNora Franzen, Valesca P Retèl, Winnie Schats, et al.
Tumori|June 21, 2008
Early phase Technology Assessment of nanotechnology in oncologyValesca P Retèl, Marjan J M Hummel, Willem H van Harten
BMJ Open|December 31, 2025
Hospital-based real-world evidence in health technology assessment: insights from a scoping review of European, Australian and North American guidance and expert interviewsZainab Al-Khayat, Nora Franzen, Valesca P Retèl, et al.
Breast Cancer Research and Treatment|January 3, 2021
Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?Danalyn Byng, Valesca P Retèl, Michael Schaapveld, et al.
Breast (Edinburgh, Scotland)|May 5, 2015
Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapyAnna Miquel-Cases, Lotte M G Steuten, Valesca P Retèl, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Value of research and value of development in early assessments of new medical technologiesValesca P Retèl, Janneke P C Grutters, Wim H van Harten, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information AnalysisAnna Miquel-Cases, Valesca P Retèl, Wim H van Harten, et al.
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Molecular profiling is rather likely to be cost effectiveValesca P Retèl, Sabine C Linn, Wim H van Harten
Breast Cancer Research and Treatment|September 28, 2011
Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of complianceValesca P Retèl, Manuela A Joore, Wim H van Harten
Molecular Oncology|June 23, 2009
Review on early technology assessments of nanotechnologies in oncologyValesca P Retèl, Marjan J M Hummel, Wim H van Harten
JAMA Oncology|March 28, 2020
Evidence Underlying Policy Proposals for Sustainable Anticancer Drug Prices: A Systematic ReviewNora Franzen, Valesca P Retèl, Winnie Schats, et al.
Tumori|June 21, 2008
Early phase Technology Assessment of nanotechnology in oncologyValesca P Retèl, Marjan J M Hummel, Willem H van Harten
BMJ Open|December 31, 2025
Hospital-based real-world evidence in health technology assessment: insights from a scoping review of European, Australian and North American guidance and expert interviewsZainab Al-Khayat, Nora Franzen, Valesca P Retèl, et al.
Breast Cancer Research and Treatment|January 3, 2021
Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?Danalyn Byng, Valesca P Retèl, Michael Schaapveld, et al.
Breast (Edinburgh, Scotland)|May 5, 2015
Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapyAnna Miquel-Cases, Lotte M G Steuten, Valesca P Retèl, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Value of research and value of development in early assessments of new medical technologiesValesca P Retèl, Janneke P C Grutters, Wim H van Harten, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2016
Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information AnalysisAnna Miquel-Cases, Valesca P Retèl, Wim H van Harten, et al.
Pageof 9